{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T04:00:58Z","timestamp":1754020858136,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"crossref","award":["IG 2017-20594"],"award-info":[{"award-number":["IG 2017-20594"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"crossref","award":["PE-2016-02361797","Ricerca Corrente"],"award-info":[{"award-number":["PE-2016-02361797","Ricerca Corrente"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012352","name":"Universit\u00e0 degli Studi di Milano","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Patients with Cushing\u2019s syndrome (CS) are at high risk of venous thromboembolism related to a hypercoagulability due to procoagulant imbalance. However, whether these alterations are reversible after disease remission is still unclear. The endogenous thrombin potential (ETP) measured with and without the addition of thrombomodulin provides a global representation of coagulation and previous data confirmed hypercoagulable profile in patients with active hypercortisolism. Aim of this study was to assess the short- and long-term modification of ETP in patients with CS after disease remission.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Design and methods<\/jats:title>\n                <jats:p>Nineteen patients with CS for whom surgical remission was achieved, were prospectively evaluated for clinical characteristics, cortisol secretion profile and ETP at different time points: (i) before surgical intervention; (ii) after 6\u00a0months and (iii) 5\u00a0years from the time of persistent remission. Nineteen healthy subjects matched for age and gender were also evaluated as control group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Before surgery, patients showed higher ETP-ratio (with\/without thrombomodulin) than controls (0.62\u2009\u00b1\u20090.09-vs-0.56\u2009\u00b1\u20090.09, <jats:italic>p\u2009<\/jats:italic>=\u20090.034). No significant correlation between ETP-ratio and cortisol secretion was found. 6 months after remission, ETP-ratio was still significantly increased compared to controls (0.64\u2009\u00b1\u20090.09-vs-0.56\u2009\u00b1\u20090.09, <jats:italic>p\u2009<\/jats:italic>=\u20090.01), but was similar to baseline (0.64\u2009\u00b1\u20090.09-vs-0.62\u2009\u00b1\u20090.09, <jats:italic>p\u2009<\/jats:italic>=\u20090.87). At 5\u00a0years, ETP-ratio showed a significant decrease (0.55\u2009\u00b1\u20090.14-vs-0.62\u2009\u00b1\u20090.09, <jats:italic>p\u2009<\/jats:italic>=\u20090.02) and was comparable to controls (0.55\u2009\u00b1\u20090.14-vs-0.56\u2009\u00b1\u20090.09, <jats:italic>p\u2009<\/jats:italic>=\u20090.7).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Plasma hypercoagulability detected in patients with active hypercortisolism persists at short-term evaluation and seems to be completely reversible after long-term remission of disease. These data, as part of a whole evaluation of thrombotic risk, can contribute to make appropriate therapeutic choice in these patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-021-01605-5","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T12:02:43Z","timestamp":1623412963000},"page":"9-16","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Evaluation of procoagulant imbalance in Cushing\u2019s syndrome after short- and long-term remission of disease"],"prefix":"10.1007","volume":"45","author":[{"given":"E.","family":"Ferrante","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. L.","family":"Serban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Clerici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Indirli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Scalambrino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Carosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Padovan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Arosio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9065-3886","authenticated-orcid":false,"given":"G.","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Tripodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,11]]},"reference":[{"key":"1605_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00805","author":"J Wagner","year":"2019","unstructured":"Wagner J, Langlois F, Lim DST et al (2019) Hypercoagulability and risk of venous thromboembolic events in endogenous Cushing\u2019s syndrome: a systematic meta-analysis. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2018.00805","journal-title":"Front Endocrinol"},{"key":"1605_CR2","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1210\/jc.2011-1661","volume":"96","author":"DJF Stuijver","year":"2011","unstructured":"Stuijver DJF, van Zaane B, Feelders RA et al (2011) Incidence of venous thromboembolism in patients with Cushing\u2019s syndrome: a multicenter cohort study. J Clin Endocrinol Metab 96:3525\u20133532. https:\/\/doi.org\/10.1210\/jc.2011-1661","journal-title":"J Clin Endocrinol Metab"},{"key":"1605_CR3","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1210\/jc.2012-3582","volume":"98","author":"OM Dekkers","year":"2013","unstructured":"Dekkers OM, Horv\u00e1th-Puh\u00f3 E, J\u00f8rgensen JOL et al (2013) Multisystem morbidity and mortality in Cushing\u2019s syndrome: a cohort study. J Clin Endocrinol Metab 98:2277\u20132284. https:\/\/doi.org\/10.1210\/jc.2012-3582","journal-title":"J Clin Endocrinol Metab"},{"key":"1605_CR4","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1055\/s-0038-1657142","volume":"47","author":"ZR Dal Bo","year":"1982","unstructured":"Dal Bo ZR, Fornasiero L, Boscaro M et al (1982) Increased factor VIII associated activities in Cushing\u2019s syndrome: a probable hypercoagulable state. Thromb Haemost 47:116\u2013117","journal-title":"Thromb Haemost"},{"key":"1605_CR5","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/00001721-199212000-00013","volume":"3","author":"GM Patrassi","year":"1992","unstructured":"Patrassi GM, Sartori MT, Viero ML et al (1992) The fibrinolytic potential in patients with Cushing\u2019s disease: a clue to their hypercoagulable state. Blood Coagul Fibrinolysis Int J Haemost Thromb 3:789\u2013793. https:\/\/doi.org\/10.1097\/00001721-199212000-00013","journal-title":"Blood Coagul Fibrinolysis Int J Haemost Thromb"},{"key":"1605_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/00001721-199904000-00006","volume":"10","author":"A Casonato","year":"1999","unstructured":"Casonato A, Pontara E, Boscaro M et al (1999) Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing\u2019s syndrome. Blood Coagul Fibrinolysis Int J Haemost Thromb 10:145\u2013151. https:\/\/doi.org\/10.1097\/00001721-199904000-00006","journal-title":"Blood Coagul Fibrinolysis Int J Haemost Thromb"},{"key":"1605_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/BF03343697","volume":"23","author":"LM Fatti","year":"2000","unstructured":"Fatti LM, Bottasso B, Invitti C et al (2000) Markers of activation of coagulation and fibrinolysis in patients with Cushing\u2019s syndrome. J Endocrinol Invest 23:145\u2013150. https:\/\/doi.org\/10.1007\/BF03343697","journal-title":"J Endocrinol Invest"},{"key":"1605_CR8","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1210\/jcem.87.8.8703","volume":"87","author":"M Boscaro","year":"2002","unstructured":"Boscaro M, Sonino N, Scarda A et al (2002) Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing\u2019s syndrome. J Clin Endocrinol Metab 87:3662\u20133666. https:\/\/doi.org\/10.1210\/jcem.87.8.8703","journal-title":"J Clin Endocrinol Metab"},{"key":"1605_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s12020-009-9186-y","volume":"36","author":"D Kastelan","year":"2009","unstructured":"Kastelan D, Dusek T, Kraljevic I et al (2009) Hypercoagulability in Cushing\u2019s syndrome: the role of specific haemostatic and fibrinolytic markers. Endocrine 36:70\u201374. https:\/\/doi.org\/10.1007\/s12020-009-9186-y","journal-title":"Endocrine"},{"key":"1605_CR10","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1210\/jc.2011-2753","volume":"97","author":"R van der Pas","year":"2012","unstructured":"van der Pas R, de Bruin C, Leebeek FWG et al (2012) The hypercoagulable state in Cushing\u2019s disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. J Clin Endocrinol Metab 97:1303\u20131310. https:\/\/doi.org\/10.1210\/jc.2011-2753","journal-title":"J Clin Endocrinol Metab"},{"key":"1605_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11102-013-0467-3","volume":"17","author":"S Koutroumpi","year":"2014","unstructured":"Koutroumpi S, Spiezia L, Albiger N et al (2014) Thrombin generation in Cushing\u2019s syndrome: do the conventional clotting indices tell the whole truth? Pituitary 17:68\u201375. https:\/\/doi.org\/10.1007\/s11102-013-0467-3","journal-title":"Pituitary"},{"key":"1605_CR12","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/cen.12491","volume":"81","author":"MCA Coelho","year":"2014","unstructured":"Coelho MCA, Vieira Neto L, Kasuki L et al (2014) Rotation thromboelastometry and the hypercoagulable state in Cushing\u2019s syndrome. Clin Endocrinol (Oxf) 81:657\u2013664. https:\/\/doi.org\/10.1111\/cen.12491","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1605_CR13","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1055\/s-0038-1657887","volume":"54","author":"GM Patrassi","year":"1985","unstructured":"Patrassi GM, Dal Bo ZR, Boscaro M et al (1985) Further studies on the hypercoagulable state of patients with Cushing\u2019s syndrome. Thromb Haemost 54:518\u2013520","journal-title":"Thromb Haemost"},{"key":"1605_CR14","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s11102-014-0600-y","volume":"18","author":"M Barbot","year":"2015","unstructured":"Barbot M, Daidone V, Zilio M et al (2015) Perioperative thromboprophylaxis in Cushing\u2019s disease: What we did and what we are doing? Pituitary 18:487\u2013493. https:\/\/doi.org\/10.1007\/s11102-014-0600-y","journal-title":"Pituitary"},{"key":"1605_CR15","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s12020-016-1027-1","volume":"56","author":"A Tripodi","year":"2017","unstructured":"Tripodi A, Ammollo CT, Semeraro F et al (2017) Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors. Endocrine 56:298\u2013307. https:\/\/doi.org\/10.1007\/s12020-016-1027-1","journal-title":"Endocrine"},{"key":"1605_CR16","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/BF03345709","volume":"32","author":"C Erem","year":"2009","unstructured":"Erem C, Nuhoglu I, Yilmaz M et al (2009) Blood coagulation and fibrinolysis in patients with Cushing\u2019s syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels. J Endocrinol Invest 32:169\u2013174","journal-title":"J Endocrinol Invest"},{"key":"1605_CR17","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1530\/eje.0.1390575","volume":"139","author":"B Ambrosi","year":"1998","unstructured":"Ambrosi B, Barbetta L, Re T et al (1998) The one microgram adrenocorticotropin test in the assessment of hypothalamic-pituitary-adrenal function. Eur J Endocrinol 139:575\u2013579","journal-title":"Eur J Endocrinol"},{"key":"1605_CR18","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1210\/jc.2004-0079","volume":"89","author":"M Terzolo","year":"2004","unstructured":"Terzolo M, Allasino B, Bosio S et al (2004) Hyperhomocysteinemia in patients with Cushing\u2019s syndrome. J Clin Endocrinol Metab 89:3745\u20133751. https:\/\/doi.org\/10.1210\/jc.2004-0079","journal-title":"J Clin Endocrinol Metab"},{"key":"1605_CR19","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s12020-015-0665-z","volume":"52","author":"M Zilio","year":"2016","unstructured":"Zilio M, Mazzai L, Sartori MT et al (2016) A venous thromboembolism risk assessment model for patients with Cushing\u2019s syndrome. Endocrine 52:322\u2013332. https:\/\/doi.org\/10.1007\/s12020-015-0665-z","journal-title":"Endocrine"},{"key":"1605_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1684\/abc.2014.1018","volume":"73","author":"C Lecut","year":"2015","unstructured":"Lecut C, Peters P, Massion PB, Gothot A (2015) Is there a place for thrombin generation assay in routine clinical laboratory? Ann Biol Clin (Paris) 73:137\u2013149. https:\/\/doi.org\/10.1684\/abc.2014.1018","journal-title":"Ann Biol Clin (Paris)"},{"key":"1605_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000071636","volume":"33","author":"HC Hemker","year":"2003","unstructured":"Hemker HC, Giesen P, Al Dieri R et al (2003) Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 33:4\u201315. https:\/\/doi.org\/10.1159\/000071636","journal-title":"Pathophysiol Haemost Thromb"},{"key":"1605_CR22","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1160\/TH16-10-0806","volume":"117","author":"A Tripodi","year":"2017","unstructured":"Tripodi A (2017) Detection of procoagulant imbalance: modified endogenous thrombin potential with results expressed as ratio of values with-to-without thrombomodulin. Thromb Haemost 117:830\u2013836. https:\/\/doi.org\/10.1160\/TH16-10-0806","journal-title":"Thromb Haemost"},{"key":"1605_CR23","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1210\/jc.2008-0125","volume":"93","author":"LK Nieman","year":"2008","unstructured":"Nieman LK, Biller BMK, Findling JW et al (2008) The diagnosis of Cushing\u2019s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93:1526\u20131540. https:\/\/doi.org\/10.1210\/jc.2008-0125","journal-title":"J Clin Endocrinol Metab"},{"key":"1605_CR24","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.beem.2009.06.001","volume":"23","author":"X Bertagna","year":"2009","unstructured":"Bertagna X, Guignat L, Groussin L, Bertherat J (2009) Cushing\u2019s disease. Best Pract Res Clin Endocrinol Metab 23:607\u2013623. https:\/\/doi.org\/10.1016\/j.beem.2009.06.001","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1605_CR25","first-page":"8","volume":"88","author":"V Chantarangkul","year":"2003","unstructured":"Chantarangkul V, Clerici M, Bressi C et al (2003) Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability. Haematologica 88:8","journal-title":"Haematologica"},{"key":"1605_CR26","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1210\/jc.2010-1942","volume":"96","author":"RN Clayton","year":"2011","unstructured":"Clayton RN, Raskauskiene D, Reulen RC, Jones PW (2011) Mortality and morbidity in Cushing\u2019s disease over 50 years in stoke-on-trent, uk: audit and meta-analysis of literature. J Clin Endocrinol Metab 96:632\u2013642. https:\/\/doi.org\/10.1210\/jc.2010-1942","journal-title":"J Clin Endocrinol Metab"},{"key":"1605_CR27","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S2213-8587(16)30005-5","volume":"4","author":"RN Clayton","year":"2016","unstructured":"Clayton RN, Jones PW, Reulen RC et al (2016) Mortality in patients with Cushing\u2019s disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. Lancet Diabetes Endocrinol 4:569\u2013576. https:\/\/doi.org\/10.1016\/S2213-8587(16)30005-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1605_CR28","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1530\/EJE-10-0583","volume":"163","author":"L Manetti","year":"2010","unstructured":"Manetti L, Bogazzi F, Giovannetti C et al (2010) Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing\u2019s syndrome: results from a prospective study before and after surgery. Eur J Endocrinol 163:783\u2013791. https:\/\/doi.org\/10.1530\/EJE-10-0583","journal-title":"Eur J Endocrinol"},{"key":"1605_CR29","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1365-2265.2012.04479.x","volume":"78","author":"D Kastelan","year":"2013","unstructured":"Kastelan D, Dusek T, Kraljevic I, Aganovic I (2013) Hypercoagulable state in Cushing\u2019s syndrome is reversible following remission. Clin Endocrinol (Oxf) 78:102\u2013106. https:\/\/doi.org\/10.1111\/j.1365-2265.2012.04479.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1605_CR30","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11239-019-01818-9","volume":"48","author":"A Tripodi","year":"2019","unstructured":"Tripodi A, Primignani M, Badiali S et al (2019) Body mass index reduction improves the baseline procoagulant imbalance of obese subjects. J Thromb Thrombolysis 48:52\u201360. https:\/\/doi.org\/10.1007\/s11239-019-01818-9","journal-title":"J Thromb Thrombolysis"},{"key":"1605_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.thromres.2018.11.027","volume":"174","author":"A Elias","year":"2019","unstructured":"Elias A, Rock W, Odetalla A et al (2019) Enhanced thrombin generation in patients with arterial hypertension. Thromb Res 174:121\u2013128. https:\/\/doi.org\/10.1016\/j.thromres.2018.11.027","journal-title":"Thromb Res"},{"key":"1605_CR32","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11239-010-0506-0","volume":"31","author":"A Tripodi","year":"2011","unstructured":"Tripodi A, Branchi A, Chantarangkul V et al (2011) Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. J Thromb Thrombolysis 31:165\u2013172. https:\/\/doi.org\/10.1007\/s11239-010-0506-0","journal-title":"J Thromb Thrombolysis"},{"key":"1605_CR33","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1001\/archinte.162.10.1182","volume":"162","author":"AW Tsai","year":"2002","unstructured":"Tsai AW, Cushman M, Rosamond WD et al (2002) Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 162:1182\u20131189. https:\/\/doi.org\/10.1001\/archinte.162.10.1182","journal-title":"Arch Intern Med"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01605-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-021-01605-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01605-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T19:15:14Z","timestamp":1641582914000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-021-01605-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,11]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1605"],"URL":"https:\/\/doi.org\/10.1007\/s40618-021-01605-5","relation":{},"ISSN":["1720-8386"],"issn-type":[{"type":"electronic","value":"1720-8386"}],"subject":[],"published":{"date-parts":[[2021,6,11]]},"assertion":[{"value":"4 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The study was approved by Milan Area 2 Ethical Committee (Study Number 4276, ID 76977). The study was performed in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All subjects gave their written informed consent for the use of their clinical data for research purposes.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}